Project UpdateJun 16, 2026, 07:36 AM
Acumen Pharma Nominates 2 EBD Candidates for Alzheimer's Treatment
AI Summary
Acumen Pharmaceuticals announced the nomination of two Enhanced Brain Delivery (EBD) development candidates, ACU301 and ACU401, for the treatment of Alzheimer's disease. This follows the exercise of an option under its collaboration agreement with JCR Pharmaceuticals, leveraging JCR's J-Brain Cargo technology with Acumen's A O-selective antibodies. Preclinical studies demonstrated significantly enhanced brain penetration (14-40x higher antibody levels in NHPs), a low risk of anemia, and suitability for subcutaneous dosing, with IND submission targeted for mid-2027.
Key Highlights
- Acumen Pharmaceuticals nominated two Enhanced Brain Delivery (EBD) development candidates (ACU301, ACU401) for Alzheimer's disease.
- The candidates combine Acumen's A\u03b2O-selective antibody expertise with JCR's J-Brain Cargo technology.
- One candidate is a bispecific antibody derived from sabirnetug; the other is a novel ACU234 antibody.
- Preclinical studies showed 14-40x higher brain penetration in non-human primates than native antibodies.
- Preclinical data suggested a low risk of anemia and no adverse events across tested species.
- Candidates exhibited favorable stability and plasma PK profiles for subcutaneous (SC) administration.
- IND-enabling activities are ongoing, targeting IND submission in mid-2027.
- The EBD technology represents the only anti-amyloid oligomer program combining a validated blood-brain barrier-penetrating technology with a therapeutic antibody tested in the clinic.
Price Impact
More from ABOS